DNB Asset Management AS Increases Holdings in Amgen Inc. $AMGN

DNB Asset Management AS grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 142,001 shares of the medical research company’s stock after acquiring an additional 2,474 shares during the quarter. DNB Asset Management AS’s holdings in Amgen were worth $46,478,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. grew its stake in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after acquiring an additional 43,884 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in Amgen by 2.3% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after acquiring an additional 3,619 shares in the last quarter. Curtis Advisory Group LLC bought a new position in Amgen in the 4th quarter worth about $1,669,000. Jones Financial Companies Lllp grew its stake in Amgen by 18.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after acquiring an additional 6,115 shares in the last quarter. Finally, Lockheed Martin Investment Management Co. bought a new position in Amgen in the 3rd quarter worth about $2,624,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on AMGN. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. The Goldman Sachs Group increased their price objective on shares of Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a research note on Friday, May 1st. TD Cowen reiterated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Daiwa Securities Group dropped their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Rothschild & Co Redburn increased their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $356.15.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by insiders.

Amgen Trading Down 3.0%

NASDAQ:AMGN opened at $326.31 on Friday. Amgen Inc. has a 52 week low of $267.73 and a 52 week high of $391.29. The firm has a 50 day moving average of $349.17 and a 200 day moving average of $342.99. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The stock has a market capitalization of $176.10 billion, a price-to-earnings ratio of 22.71, a PEG ratio of 3.38 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the prior year, the company posted $4.90 earnings per share. Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen’s dividend payout ratio is presently 70.15%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.